nach oben

International Urology and Nephrology

Erschienen in:

05.03.2018 | Nephrology - Original Paper

Silencing of CXCL12 performs a protective effect on C5b-9-induced injury in podocytes

verfasst von: Wengang Sha, Lei Shen, Ling Zhou, Deyu Xu, Jing Yang, Guoyuan Lu

Erschienen in: International Urology and Nephrology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Podocytes, terminal differentiation cell in glomerulu, are crucial to kidney-related diseases such as membranous nephropathy (MN). MN is characterized by podocyte injury and glomerular basement membrane thickening. This paper focused to investigate the expression of chemokine (C-X-C motif) ligand 12 (CXCL12) in MN patients and its possible role in podocyte injury.

Methods

Through the enzyme-linked immunosorbent assay, CXCL12 level in the serum and urine of MN patients was examined. Further, several assays of cell viability, apoptosis, quantitative real-time PCR and western blot were applied to explore the effects of CXCL12 in the model of podocyte injury.

Results

We found a significant increase of CXCL12 in serum and urine of MN patients, which indicated that CXCL12 may be involved in the progression of MN. And in vitro C5b-9-induced podocyte injury model, the proliferation of podocytes was inhibited whereas CXCL12/CXCR4 and phosphorylated STAT3 (p-STAT3) were increased. Silencing of CXCL12 remarkably promoted cell proliferation, inhibited cell apoptosis and suppressed CXCL12/CXCR4, p-STAT3 and caspase 3. Consistently, STAT3 inhibitor and berberine (a CXCL12 antagonist) also reduced CXCL12 treatment-induced apoptosis.

Conclusions

All data suggested that silencing of CXCL12 had a protective effect on podocyte injury, which may be through inhibiting CXCL12/STAT3 signaling pathway.

Ayalon R Jr, Beck LH Jr (2015) Membranous nephropathy: not just a disease for adults. Pediatr Nephrol 30(1):31–39CrossRefPubMed

Nachman P, Jennette J, Falk R (2008) Primary glomerular disease. In: Brenner BM (ed) Brenner and Rector’s The Kidney. Saunders, Philadelphia, PA, pp 987–1066

Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14(7):1851–1857CrossRefPubMed

Sinico RA, Mezzina N, Trezzi B, Ghiggeri G, Radice A (2016) Immunology of membranous nephropathy: from animal models to humans. Clin Exp Immunol 183(2):157CrossRefPubMed

Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschênes G, Ronco PM (2002) Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346(26):2053CrossRefPubMed

Kuroki A (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med (NEJM) 361(1):11–21CrossRef

Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Kai F, Helmchen U, Stahl RAK (2011) An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transp 26(8):2526–2532CrossRef

Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L (2010) Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol (JASN) 21(3):507CrossRef

Murtas C, Ravani P, Ghiggeri GM (2011) New insights into membranous glomerulonephritis: from bench to bedside. Nephrol Dial Transp 26(8):2428CrossRef

10.

Bruschi M, Carnevali ML, Murtas C, Candiano G, Petretto A, Prunotto M, Gatti R, Argentiero L, Magistroni R, Garibotto G (2011) Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens. J Proteomics 74(10):2008–2017CrossRefPubMed

11.

Burns JM, Summers BC, Yu W, Melikian A, Berahovich R, Miao Z, Penfold MET, Sunshine MJ, Dan RL, Kuo CJ (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203(9):2201CrossRefPubMedPubMedCentral

12.

Sayyed SG, Hägele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D, Klussmann S, Anders HJ (2009) Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52(11):2445–2454CrossRefPubMed

13.

Liao X, Pirapakaran T, Luo XM (2016) Chemokines and chemokine receptors in the development of lupus nephritis. Mediat Inflamm (2, article e63)

14.

Schramme A, Abdelbakky MS, Gutwein P, Obermüller N, Baer PC, Hauser IA, Ludwig A, Gauer S, Schäfer L, Sobkowiak E (2008) Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int 74(3):328–338CrossRefPubMed

15.

Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C (2007) Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 179(10):7166–7175. https://doi.org/10.4049/jimmunol.179.10.7166 CrossRefPubMed

16.

Gutwein P, Abdel-Bakky MS, Schramme A, Kai D, Kämpfer-Kolb N, Amann K, Hauser IA, Obermüller N, Bartel C, Abdel-Aziz AAH (2009) CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol 174(6):2061–2072CrossRefPubMedPubMedCentral

17.

Stark GR, Darnell JE Jr (2012) The JAK-STAT pathway at twenty. Immunity 36(4):503–514CrossRefPubMedPubMedCentral

18.

Wegenka UM, Buschmann J, Lütticken C, Heinrich PC, Horn F (1993) Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 13(1):276–288CrossRefPubMedPubMedCentral

19.

Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T (1994) Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263(5143):89CrossRefPubMed

20.

Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T (1994) Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77(1):63CrossRefPubMed

21.

Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282(28):20059CrossRefPubMed

22.

Dai Y, Gu L, Yuan W, Yu Q, Ni Z, Ross MJ, Kaufman L, Xiong H, Salant DJ, He JC, Chuang PY (2013) Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis. Kidney Int 84(5):950–961CrossRefPubMedPubMedCentral

23.

Feng X, Lu TC, Chuang PY, Fang W, Ratnam K, Xiong H, Ouyang X, Shen Y, Levy DE, Hyink D (2009) Reduction of Stat3 activity attenuates HIV-induced kidney injury. J Am Soc Nephrol (JASN) 20(10):2138CrossRef

24.

Liu R, Zhong Y, Li X, Chen H, Jim B, Zhou MM, Chuang PY, He JC (2014) Role of transcription factor acetylation in diabetic kidney disease. Diabetes 63(7):2440–2453CrossRefPubMedPubMedCentral

25.

Zhang W, Chen X, Shi S, Wei R, Wang J, Yamanaka N, Hong Q (2005) Expression and activation of STAT3 in chronic proliferative immune complex glomerulonephritis and the effect of fosinopril. Nephrol Dial Transp 20(5):892CrossRef

26.

Arakawa T, Masaki T, Hirai T, Doi S, Kuratsune M, Arihiro K, Kohno N, Yorioka N (2008) Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis. Nephrol Dial Transp 23(11):3418–3426CrossRef

27.

He JC, Husain M, Sunamoto M, D’Agati VD, Klotman ME, Iyengar R, Klotman PE (2004) Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Investig 114(5):643–651CrossRefPubMed

28.

Liu X, Xiao Q, Bai X, Yu Z, Sun M, Zhao H, Mi X, Wang E, Yao W, Jin F (2014) Activation of STAT3 is involved in malignancy mediated by CXCL12-CXCR4 signaling in human breast cancer. Oncol Rep 32(6):2760CrossRefPubMed

29.

Ma H, Sandor DG Jr, Beck LH (2013) The role of complement in membranous nephropathy. Semin Nephrol 33(6):531CrossRefPubMedPubMedCentral

30.

Hong JY, Kang B, Ahyoun K, Seoyeon H, Jinhee A, Sunhwa L, Jonghyen K, Jae-Hak P, Doo-Sung C (2011) Development of a highly sensitive real-time one step RT-PCR combined complementary locked primer technology and conjugated minor groove binder probe. Virol J 8(1):1–6CrossRef

31.

Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ (2003) DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Investig 111(6):877CrossRefPubMed

32.

Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak J, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Neurath MF (2010) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. https://doi.org/10.1038/nm1110-1341 CrossRef

33.

Mitsuyama K, Matsumoto S, Rosejohn S, Suzuki A, Hara T, Tomiyasu N, Handa K, Tsuruta O, Funabashi H, Scheller J (2006) STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 55(9):1263–1269CrossRefPubMedPubMedCentral

34.

Finotto S, Eigenbrod T, Karwot R, Boross I, Doganci A, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Rosejohn S (2007) Local blockade of IL-6R signaling induces lung CD4+T cell apoptosis in a murine model of asthma via regulatory T cells. Int Immunol 19(6):685–693CrossRefPubMed

35.

Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J (2008) Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3):1021CrossRefPubMed

36.

Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Scheller J, Rosejohn S, Kado S, Takada T (2010) Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 184(3):1543–1551CrossRefPubMed

37.

Greenhill CJ, Rosejohn S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ, Mansell A, Jenkins BJ (2010) IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 52(1–2):1199

38.

Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19(4):456–469CrossRefPubMed

39.

Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML (2011) IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 71(2):424–434CrossRefPubMed

40.

Jasiewicz M, Knapp M, Waszkiewicz E, Ptaszynska-Kopczynska K, Szpakowicz A, Sobkowicz B, Musial WJ, Kaminski KA (2015) Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. Cytokine 76(2):187–192CrossRefPubMed

41.

Dalla VM, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, Plebani M, Fioretto P (2005) Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol (JASN) 16(Suppl 1):S78CrossRef

42.

Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, Endoh M, Nomoto Y, Sakai H (1995) In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44(10):1233–1238CrossRefPubMed

Titel: Silencing of CXCL12 performs a protective effect on C5b-9-induced injury in podocytes
verfasst von: Wengang Sha
Lei Shen
Ling Zhou
Deyu Xu
Jing Yang
Guoyuan Lu
Publikationsdatum: 05.03.2018
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 8/2018
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-018-1799-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Are iso-osmolar, as compared to low-osmolar, contrast media cost-effective in patients undergoing cardiac catheterization? An economic analysis

Mesenchymal stem cells alleviate acute kidney injury by down-regulating C5a/C5aR pathway activation

Long term outcomes in the use of ileal ureter for radiation-induced ureteral strictures

Comparisons of percutaneous versus retroperitoneoscopic cryoablation for renal masses

Dynamic assessment of human sperm DNA damage I: the effect of seminal plasma-sperm co-incubation after ejaculation